Arch Therapeutics Inc (ARTH)

[GhostMOMENTUM]

haha I hear you on that!

I feel that once $1 breaks and holds, with a continued increase in the fundamental value (production, distribution, selling, then FDA, etc) I assume price will be driven substantially higher with the first goal of uplisting it onto the Nasdaq.

OTC greatly restricts the potential shareholder base because many brokerage firms/ and/or most advisors at those firms, aren't allowed by compliance to purchase OTC stocks like this. This goes for the institutional side as well. I believe the percentage of financial advisors in the US that are allowed to purchase OTC stocks is somewhere between 5 and 8%. And of that 5-8%, most won't dare put their career on the line to recommend something like this, or even look at it for more than 2 seconds. An uplisting I believe is high on the priority list once positive human trial results are hopefully announced.